Can we still learn from single center experience after PARTNER?

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• Transcatheter aortic valve replacement (TAVR) is established for severe aortic stenosis in patients ineligible for surgical aortic valve replacement (AVR).
• The PARTNER trial demonstrated TAVR's non-inferiority to AVR in high-risk individuals.
• A study by Ben-Dor et al. examined outcomes of high-risk patients referred for the PARTNER trial, including those treated medically, with AVR, or TAVR.

Purpose of the Study:

• To evaluate and compare the outcomes of high-risk patients with severe aortic stenosis treated with TAVR, AVR, or medical therapy.
• To identify independent predictors of mortality in this patient cohort.

Main Methods:

• Retrospective analysis of high-risk patients with severe aortic stenosis referred for PARTNER trial participation.
• Stratification of outcomes based on treatment received: TAVR, AVR, or medical therapy (with or without balloon aortic valvuloplasty).
• Comparison of baseline characteristics and mortality rates across treatment groups.

Main Results:

• Patients treated medically exhibited significantly higher mortality compared to those receiving TAVR or AVR.
• Survival rates for TAVR and AVR were comparable.
• Independent predictors of mortality were identified through statistical analysis.

Conclusions:

• TAVR and AVR provide similar survival benefits for high-risk patients with severe aortic stenosis.
• Medical management alone is associated with increased mortality in this population.
• Further research is warranted to refine treatment strategies and understand mortality predictors.